Exxonmobil Investment Management Inc. TX cut its holdings in Baxter International Inc (NYSE:BAX) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,706 shares of the medical instruments supplier’s stock after selling 11,835 shares during the quarter. Exxonmobil Investment Management Inc. TX’s holdings in Baxter International were worth $5,152,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of BAX. Gofen & Glossberg LLC IL boosted its position in Baxter International by 1.3% during the second quarter. Gofen & Glossberg LLC IL now owns 15,354 shares of the medical instruments supplier’s stock worth $930,000 after purchasing an additional 203 shares in the last quarter. KCM Investment Advisors LLC boosted its position in Baxter International by 2.9% during the second quarter. KCM Investment Advisors LLC now owns 7,625 shares of the medical instruments supplier’s stock worth $462,000 after purchasing an additional 214 shares in the last quarter. Harvest Fund Management Co. Ltd boosted its position in Baxter International by 8.4% during the second quarter. Harvest Fund Management Co. Ltd now owns 2,928 shares of the medical instruments supplier’s stock worth $177,000 after purchasing an additional 226 shares in the last quarter. Thrivent Financial For Lutherans boosted its position in Baxter International by 3.0% during the second quarter. Thrivent Financial For Lutherans now owns 18,651 shares of the medical instruments supplier’s stock worth $1,129,000 after purchasing an additional 540 shares in the last quarter. Finally, Clear Perspective Advisors LLC boosted its position in Baxter International by 13.1% during the second quarter. Clear Perspective Advisors LLC now owns 4,823 shares of the medical instruments supplier’s stock worth $292,000 after purchasing an additional 558 shares in the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

BAX has been the topic of a number of research analyst reports. Evercore ISI initiated coverage on Baxter International in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $71.00 target price on the stock. Bank of America upgraded Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Raymond James Financial upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 target price on the stock in a research report on Wednesday, January 3rd. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a research report on Tuesday, October 10th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $65.00 target price on shares of Baxter International in a research report on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $68.64.

In related news, Director Third Point Llc sold 5,000,000 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $64.23, for a total value of $321,150,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Giuseppe Accogli sold 28,641 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,061,991 shares of company stock valued at $325,245,035. Insiders own 0.05% of the company’s stock.

Baxter International Inc (NYSE:BAX) opened at $68.43 on Thursday. Baxter International Inc has a 1-year low of $45.47 and a 1-year high of $69.65. The firm has a market capitalization of $37,280.00, a price-to-earnings ratio of 36.99, a PEG ratio of 2.08 and a beta of 0.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The company had revenue of $2.71 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same period in the previous year, the firm posted $0.56 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. equities research analysts anticipate that Baxter International Inc will post 2.43 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st were issued a $0.16 dividend. The ex-dividend date was Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.94%. Baxter International’s dividend payout ratio (DPR) is 34.59%.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/exxonmobil-investment-management-inc-tx-has-5-15-million-position-in-baxter-international-inc-bax/1802428.html.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.